The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
Open accessAbstract
OBJECTIVES: A randomized, parallel controlled, open-label clinical trial was conducted to evaluate the effect of a botanic compound berberine (BBR) on NAFLD. METHODS: A randomized, parallel controlled, open-label clinical trial was conducted in three medical centers (NIH Registration number: NCT00633282). A total of 184 eligible patients with NAFLD were enrolled and randomly received (i) lifestyle intervention (LSI), (ii) LSI plus pioglitazone (PGZ) 15mg qd, and (iii) LSI plus BBR 0.5g tid, respectively, for 16 weeks. Hepatic fat content (HFC), serum glucose and lipid profiles, liver enzymes and serum and urine BBR concentrations were assessed before and after treatment. We also analyzed hepatic BBR content and expression of genes related to glucose and lipid metabolism in an animal model of NAFLD treated with BBR. RESULTS: As compared with LSI, BBR treatment plus LSI resulted in a significant reduction of HFC (52.7% vs 36.4%, p = 0.008), paralleled with better improvement in body weight, HOMA-IR, and serum lipid profiles (all p<0.05). BBR was more effective than PGZ 15mg qd in reducing body weight and improving lipid profile. BBR-related adverse events were mild and mainly occurred in digestive system. Serum and urine BBR concentrations were 6.99ng/ml and 79.2ng/ml, respectively, in the BBR-treated subjects. Animal experiments showed that BBR located favorably in the liver and altered hepatic metabolism-related gene expression. CONCLUSION: BBR ameliorates NAFLD and related metabolic disorders. The therapeutic effect of BBR on NAFLD may involve a direct regulation of hepatic lipid metabolism. TRIAL REGISTRATION: ClinicalTrials.gov NCT00633282.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Several pharmacologic interventions have been attempted to treat NAFLD, and the agents targeting insulin resistance such as thiazolidinediones [5,6,7] have yielded promising results.”
BackgroundA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Self-citationon behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“LSI (including dietary modification and exercise) was conducted following the standardized recommendation [19].”
MethodAithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721 · cited 1×
“Several pharmacologic interventions have been attempted to treat NAFLD, and the agents targeting insulin resistance such as thiazolidinediones [5,6,7] have yielded promising results.”
BackgroundTreatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573 · cited 2×
“demonstrated that BBR had a robust glucose-lowering effect, accompanying with a significantly increase of glucose disposal rate through a randomized, double-blind, and placebo-controlled clinical trial [13].”
BackgroundResultChen, W., Miao, Y.-Q., Fan, D.-J., Yang, S.-S., Lin, X., Meng, L.-K., & Tang, X. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-011-9632-z · Cited by 363 · cited 1×
“Several studies reported that the BBR had an extreme low bioavailability of less than 1% in BBR-treated animals [25,26], therefore it was believed that BBR was not absorbable in human gastrointestinal tract and its beneficial effects on hepatic fat, insulin resistance as well as glucose and lipid metabolism mainly dep…”
BackgroundTissue Distribution of Berberine and Its Metabolites after Oral Administration in Rats
Tan, X.-S., Ma, J.-Y., Feng, R., Ma, C., Chen, W.-J., Sun, Y.-P., Fu, J., Huang, M., He, C.-Y., Shou, J.-W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077969 · Cited by 266 · cited 2×
“concentrations of BBR and its metabolites were measured by LC-MS/MS as described in detail previously [20].”
BackgroundMethodSelf-citationLee, K., Kerner, J., & Hoppel, C. L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228692 · Cited by 254 · cited 1×
“MTTP was for the assembly and secretion of apoB-containing lipoproteins (VLDL and LDL)[15], CPT-1a was a part of the outer membrane fatty acid transfer complex and catalyzed the primary regulated step in overall mitochondrial fatty acid oxidation[30].”
Background
Cited by
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, S. T. S., Šmejkal, K., Malaník, M., et al. (2019) · Theranostics · doi:10.7150/thno.30787 · Cited by 465
Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis
Spahis, S., Delvin, E., Borys, J.-M., & Levy, E. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6776 · Cited by 386
Berberine and barberry (Berberis vulgaris): A clinical review
Imenshahidi, M., & Hosseinzadeh, H. (2019) · Phytotherapy Research · doi:10.1002/ptr.6252 · Cited by 368
Berberis Vulgaris and Berberine: An Update Review
Imenshahidi, M., & Hosseinzadeh, H. (2016) · Phytotherapy Research · doi:10.1002/ptr.5693 · Cited by 359
Quantification of liver fat content with CT and MRI: state of the art
Starekova, J., Hernando, D., Pickhardt, P. J., & Reeder, S. B. (2021) · Radiology · doi:10.1148/radiol.2021204288 · Cited by 320
Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway
Zhu, X., Bian, H., Wang, L., Sun, X., Xu, X., Yan, H., Xia, M., Chang, X., Lu, Y., Li, Y., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.06.019 · Cited by 273
Self-citationInduction of Adipose Tissue Browning as a Strategy to Combat Obesity
Kuryłowicz, A., & Puzianowska-Kuźnicka, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176241 · Cited by 219
Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine
Wang, Y., Tong, Q., Shou, J.-W., Zhao, Z.-X., Li, X.-Y., Zhang, X.-F., Ma, S.-R., He, C.-Y., Lin, Y., Wen, B.-Y., et al. (2017) · Theranostics · doi:10.7150/thno.18290 · Cited by 131
Self-citationYe, Y., Liu, X., Wu, N., Han, Y., Wang, J., Yu, Y., & Chen, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.653887 · Cited by 109
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107
Och, A., Och, M., Nowak, R., Podgórska, D., & Podgórski, R. (2022) · Molecules · doi:10.3390/molecules27041351 · Cited by 104
Glass, O., Filozof, C., Noureddin, M., Berner-Hansen, M., Schabel, E., Omokaro, S. O., Schattenberg, J. M., Barradas, K., Miller, V., Francque, S., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.030 · Cited by 89
Zhou, H., Ma, C., Wang, C., Gong, L., Zhang, Y., & Li, Y. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173976 · Cited by 73
The mechanism of berberine alleviating metabolic disorder based on gut microbiome
Wang, H., Zhang, H., Gao, Z., Zhang, Q., & Gu, C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.854885 · Cited by 69
Asbaghi, O., Ghanbari, N., shekari, M., Reiner, Ž., Amirani, E., Hallajzadeh, J., Mirsafaei, L., & Asemi, Z. (2020) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2020.04.010 · Cited by 47
Yang, S., Li, D., Yu, Z., Li, Y., & Wu, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.709629 · Cited by 40
“This trial demonstrated that BBR combined with lifestyle treatment significantly reduced hepatic fat content and improved body weight, lipid profiles, and homeostatic model assessment-IR (Yan et al., 2015).”
BackgroundSun, X., Li, F., Yan, H., Chang, X., Yao, X., Yang, X., Wu, S., Suo, Y., Zhu, X., Wang, C., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.10.012 · Cited by 30
Self-citationZamani, M., Zarei, M., Nikbaf-Shandiz, M., Hosseini, S., Shiraseb, F., & Asbaghi, O. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1013055 · Cited by 28
Li, M., Liu, Y., Qiu, Y., Zhang, J., Zhang, Y., Zhao, Y., Jia, Q., & Li, J. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113899 · Cited by 21
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis
Komolafe, O., Buzzetti, E., Linden, A., Best, L. M., Madden, A. M., Roberts, D., Chase, T. J., Fritche, D., Freeman, S. C., Cooper, N. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013157.pub2 · Cited by 21
Rafiei, H., Yeung, M., Kowalski, S., Krystal, G., & Elisia, I. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1234300 · Cited by 21
Metadata
- Authors
- Yan, H.-M., Xia, M.-F., Wang, Y., Chang, X.-X., Yao, X.-Z., Rao, S.-X., Zeng, M.-S., Tu, Y.-F., Feng, R., Jia, W.-P., Liu, J., Deng, W., Jiang, J.-D., & Gao, X.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-08-07
- Volume
- 10
- Issue
- 8
- Pages
- e0134172
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2211572047
- Cited by
- 229
- References
- 9
- FWCI
- 7.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.